Analyst Ratings for Biohaven Pharmaceutical Holding (BHVN)
BHVN Rating Summary
BHVN Price Target Summary
- Highest: $63.00 (H.C. Wainwright)
- Lowest: $31.00 (Cantor Fitzgerald)
- Average: $52.50
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$52.50 (-4%)
* Over Last 12-Mos
Rating Score: 7.8 / 10 Percentile Rank: 82%
Rating Score: 7.8 / 10 Percentile Rank: 82%
Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
---|---|---|---|---|---|---|---|---|
2/16/2024 | RBC Capital » Updated 3/1/2024 |
Leonid Timashev | New Coverage | Outperform (N/A) |
61.00 (62.00) |
49.11 (54.69) |
11.36% | Details |
2/6/2024 | UBS | Ashwani Verma | New Coverage | Buy (N/A) |
59.00 (N/A) |
44.79 (54.69) |
22.1% | Details |
BHVN Ratings News
- RBC Capital Starts Biohaven Pharmaceutical Holding (BHVN) at Outperform, Sees Nearer-term Catalysts
- UBS Starts Biohaven Pharmaceutical Holding (BHVN) at Buy, 'Diversified innovative pipeline with multiple upside drivers'
- Healthcare a contrarian idea into 2024 - these stocks could see upside
- See More